Ocuphire Pharma, Inc.

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

For more details, click here for the full news release.

Continue

Investor Relations

Latest News

View All News

Upcoming Events

View All Events

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022

Latest Annual Filing

Fiscal Year Ended Dec 31, 2021

View Filing

Stock Information

Company Overview

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.

Download Corporate Presentation

Leadership

View Management Team View Board of Directors

Investor Contact Information

Company

Ocuphire Pharma, Inc.
37000 Grand River Ave., Suite 120
Farmington Hills, MI 48335
T: 248-681-9815
[email protected]

Investor Relations

LifeSci Advisors
250 West 55th Street, Suite 3401
New York, NY 10019
T: 646-889-1200
[email protected]

Transfer Agent

American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
www.astfinancial.com